Axa’s Epizyme, Inc EPZM Stock Holding History

Axa’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-31,800	Closed	-$511K	–	1377
2020 Q2	$511K	Buy	31,800 +18,900	+147%	+$330K	﹤0.01%	1053
2020 Q1	$200K	Buy	+12,900	New	+$277K	﹤0.01%	1097
2019 Q1	–	Sell	-67,400	Closed	-$415K	–	1409
2018 Q4	$415K	Hold	67,400	–	–	﹤0.01%	1126
2018 Q3	$714K	Buy	+67,400	New	+$769K	﹤0.01%	1095
2014 Q3	–	Sell	-73,000	Closed	-$2.27M	–	1497
2014 Q2	$2.27M	Hold	73,000	–	–	0.01%	745
2014 Q1	$1.66M	Buy	+73,000	New	+$2.21M	0.01%	811

Other funds holding EPZM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Axa's EPZM Position: Q3 2020 in Review

Axa sold out of Epizyme, Inc (EPZM) in Q3 2020, closing a stake of 31,800 shares — an estimated $511K sold.

Axa first reported a position in EPZM in Q1 2014 and held it in 6 quarters. The position peaked at $2.27M in Q2 2014. 151 funds tracked by Wall St. Rank hold EPZM as of Q3 2020.

Axa reported no remaining Epizyme, Inc position as of Q3 2020 after selling out during the quarter.
Axa sold 31,800 Epizyme, Inc shares in Q3 2020, an estimated $511K.
Axa first reported a position in Epizyme, Inc in Q1 2014 and held it in 6 quarters.
Axa's Epizyme, Inc position peaked at $2.27M in Q2 2014.
151 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2020.

Based on Axa's 13F filing for Q3 2020, filed 13 Nov 2020.